Aim: The aim of this article is to analyze and summarize the current literature on the use of autologous serum eye drops for ocular surface disorders in the last 10 years and to evaluate their potential therapeutic advantages.
Materials and Methods: А research in the electronic database PubMed for a 10-year period (November, 2011–November, 2021) has been performed. A combination of following keywords has been used: “blood”, “serum”, “eye drops”, “ocular surface disease”. In addition, referent lists of the most suitable articles have been checked in order to identify acceptable materials, which have not been covered by the initial literature research. Publications in English and full-text only have been selected.
Results: A total of 51 articles with the aforementioned keywords have been found. The full text of 28 of them, corresponding to the inclusion criteria, has been revised. Fourteen articles about appliance of serum eye drops for ocular surface disorders have been found; 2 articles about the use of drops from platelet-derived products, 4 with appliance of umbilical cord blood serum eye drops, 7 comparing the effectiveness between three types of blood derivatives and conventional therapy, and 1 review of the literature.
Conclusion: Use of blood products for treatment of ocular surface disorders has had growing popularity in the last years due to their good safety profile and effectivity. For their implementation in everyday clinical practice, more randomized clinical trials and internationally admitted guidelines are needed.
Anitua E, Muruzabal F, de la Fuente M, Merayo J, Durán J, Orive G. Plasma Rich in Growth Factors for the Treatment of Ocular Surface Diseases. Curr Eye Res. 2016 Jul 2;41(7):875–82.
Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini M, Campos EC. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2017 Aug;56(4):595–604.
Franchini M, Cruciani M, Mengoli C, Marano G, Capuzzo E, Pati I, et al. Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis. Blood Transfus. 2019 May;17(3):200–9.
Hussain M, Shtein RM, Sugar A, Soong HK, Woodward MA, DeLoss K, et al. Long-term Use of Autologous Serum 50% Eye Drops for the Treatment of Dry Eye Disease. Cornea. 2014 Dec;33(12):1245–51.
Ma I-H, Chen LW, Tu W-H, Lu C-J, Huang C-J, Chen W-L. Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome. Taiwan J Ophthalmol. 2017;7(4):213–20.
Semeraro F, Forbice E, Braga O, Bova A, Di Salvatore A, Azzolini C. Evaluation of the Efficacy of 50% Autologous Serum Eye Drops in Different Ocular Surface Pathologies. BioMed Res Int. 2014;2014:826970.
Rybickova I, Vesela V, Fales I, Skalicka P, Jirsova K. Apoptosis of conjunctival epithelial cells before and after the application of autologous serum eye drops in severe dry eye disease. Biomed Pap. 2016 Jun 24;160(2):271–5.
Celebi ARC, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):619–26.
Giannaccare G, Buzzi M, Fresina M, Velati C, Versura P. Efficacy of 2-Month Treatment With Cord Blood Serum Eye Drops in Ocular Surface Disease: An In Vivo Confocal Microscopy Study. Cornea. 2017 Aug;36(8):915–21.
Giannaccare G, Versura P, Buzzi M, Primavera L, Pellegrini M, Campos EC. Blood derived eye drops for the treatment of cornea and ocular surface diseases. Transfus Apher Sci. 2017 Aug;56(4):595–604.
Yoon KC. Use of umbilical cord serum in ophthalmology. Chonnam Med J. 2014 Dec;50(3):82–5.
Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res. 2014 Feb;119:27–34.
Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res. 2015 Jun;135:118–26.
Anitua E, de la Fuente M, Muruzabal F, Riestra A, Merayo-Lloves J, Orive G. Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Exp Eye Res. 2015 Jun;135:118–26.
Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999 Oct;106(10):1984–9.
Sanchez-Avila RM, Merayo-Lloves J, Riestra AC, Fernandez-Vega Cueto L, Anitua E, Begoña L, et al. Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops. Int Ophthalmol. 2018 Jun;38(3):1193–204.
Buzzi M, Versura P, Grigolo B, Cavallo C, Terzi A, Pellegrini M, et al. Comparison of growth factor and interleukin content of adult peripheral blood and cord blood serum eye drops for cornea and ocular surface diseases. Transfus Apher Sci Off J World Apher Assoc Off J Eur Soc Haemapheresis. 2018 Aug;57(4):549–55.
Jongkhajornpong P, Numthavaj P, Anothaisintawee T, Lekhanont K, McKay G, Attia J, et al. Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol. BMJ Open. 2021 Jun 30;11(6):e048479.
Anitua E, Muruzabal F, de la Fuente M, Riestra A, Merayo-Lloves J, Orive G. PRGF exerts more potent proliferative and anti-inflammatory effects than autologous serum on a cell culture inflammatory model. Exp Eye Res. 2016 Oct;151:115–21.
